Symptoms: a sharp increase in sweating, palpitations, tremors, hunger, agitation, paresthesia in the mouth, pallor, headache, in severe cases — hypoglycemic coma.
Treatment: ingestion of sugar or foods rich in carbohydrates, in severe cases-the introduction of glucose (20-40 ml of 40% solution in/in) and glucagon (in/m, p/k, in/in).
Hypersensitivity, hypoglycemia.
MAO inhibitors, non-selective beta-blockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, fenfluramine and drugs containing ethanol, enhance the hypoglycemic effect, oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations and tricyclic antidepressants — weaken. Reserpine and salicylates can both weaken and enhance the hypoglycemic effect.
Hypoglycemia, allergic reactions (skin rash), transient refractive errors (usually at the beginning of therapy), with prolonged use — lipodystrophy at the injection site.
Patients receiving more than 100 units/day of Brinsulmidi CHSP, when changing the drug, it is advisable to be hospitalized.
The transition from one type of insulin to another should be carried out under the control of blood glucose levels.
With the initial appointment, a change in the type of insulin or the occurrence of stressful situations during treatment, it is possible to reduce the ability to drive vehicles and mechanisms, to other potentially dangerous activities that require increased attention and speed of reaction.
With changes in the nature and diet, significant physical exertion, infectious diseases, surgical interventions, pregnancy, thyroid dysfunction, Addison's disease, hypopituitarism, renal failure, and in patients over 65 years of age, it is necessary to adjust the dose.
Insulin lowers the tolerance for alcohol.
Diabetes mellitus (type 1) in adults, diabetes mellitus (type 2) (in the case of resistance to oral hypoglycemic agents, including partial during combination therapy, against the background of intercurrent diseases, during pregnancy).
In a place protected from light, at a temperature of 2-8 °C. Do not allow freezing.
Keep out of reach of children.
Shelf life of the drug Brinsulmidi CHSP 40 units/ml2,5 года.Do not use after the expiration date indicated on the package.
1 ml of suspension for injection contains 40 units of human insulin-protamine, as well as 1.6 mg of metacresol, 0.7 mg of phenol, sodium phosphate dihydrate, glycerin as a preservative, in glass bottles of 10 ml, in a cardboard pack of 1 bottle.
N / a, 1-2 times a day, the dose is determined individually, before use, the bottle is gently shaken. The drug must be administered immediately after the set in the syringe. A daily dose exceeding 0.6 U / kg should be administered as two injections in different areas of the body.
A10AB01 Human Insulin
